1. Home
  2. ADAP
  3. ADAP News

Latest Adaptimmune Therapeutics plc (ADAP) News on October 14, 2025

ADAP

MT Newswires

4 days ago

European Equities Traded in the US as American Depositary Receipts Fall in Friday Trading, Down 2.8% for Week

ADAP

MT Newswires

5 days ago

European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading

ADAP

MT Newswires

6 days ago

European Equities Traded in the US as American Depositary Receipts Track Higher in Wednesday Trading

ADAP

MT Newswires

7 days ago

European Equities Traded in the US as American Depositary Receipts Lower in Tuesday Trading

ADAP

MT Newswires

8 days ago

European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading

ADAP

MT Newswires

a month ago

European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading

ADAP

MT Newswires

a month ago

European Equities Traded in the US as ADRs Are Little Changed in Friday Trading

ADAP

MT Newswires

a month ago

European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading

ADAP

MT Newswires

4 months ago

Mizuho Downgrades Adaptimmune Therapeutics to Neutral From Outperform, Cuts Price Target to $0.50 From $1.50 on Solvency Concerns

ADAP

MT Newswires

4 months ago

European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading

ADAP

MT Newswires

4 months ago

European Equities Traded in the US as American Depositary Receipts Edge Lower in Monday Trading

ADAP

MT Newswires

4 months ago

European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading

Adaptimmune Therapeutics PLC (ADAP) Q1 2025 Earnings Call Highlights: Strong Tecelra Launch ...
ADAP

GuruFocus.com

5 months ago

Adaptimmune Therapeutics PLC (ADAP) Q1 2025 Earnings Call Highlights: Strong Tecelra Launch ...

Adaptimmune Reports Q1 Financial Results and Provides Business Update
ADAP

Newsfile

5 months ago

Adaptimmune Reports Q1 Financial Results and Provides Business Update

What To Expect From Adaptimmune Therapeutics PLC (ADAP) Q1 2025 Earnings
ADAP

GuruFocus.com

5 months ago

What To Expect From Adaptimmune Therapeutics PLC (ADAP) Q1 2025 Earnings

Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025
ADAP

Newsfile

5 months ago

Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025

ADAP

Zacks Small Cap Research

7 months ago

ADAP 4Q24 Earnings Review: EPS Miss on 1x Restructuring/Impairment Costs; Potential Capital Raise Adds Risk to the Story

Earnings To Watch: Adaptimmune Therapeutics PLC (ADAP) Reports Q4 2024 Result
ADAP

GuruFocus.com

7 months ago

Earnings To Watch: Adaptimmune Therapeutics PLC (ADAP) Reports Q4 2024 Result

Adaptimmune Therapeutics PLC (ADAP) (Q4 2024) Earnings Call Highlights: Strategic Growth and ...
ADAP

GuruFocus.com

7 months ago

Adaptimmune Therapeutics PLC (ADAP) (Q4 2024) Earnings Call Highlights: Strategic Growth and ...

ADAP

Zacks Small Cap Research

7 months ago

ADAP: 4Q24 Business Update: Tecelra Launch Progressing + Incremental Cost Savings; Banker-Led Process to Explore Strategic Options

Adaptimmune Provides Q4 and Full Year 2024 Business Update
ADAP

Newsfile

7 months ago

Adaptimmune Provides Q4 and Full Year 2024 Business Update

From cancer vaccines to COPD treatments, these 10 companies are developing innovative medicines
ADAP

FastCompany

7 months ago

From cancer vaccines to COPD treatments, these 10 companies are developing innovative medicines

Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025
ADAP

Newsfile

7 months ago

Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025

Adaptimmune Therapeutics plc's (NASDAQ:ADAP) top owners are retail investors with 50% stake, while 25% is held by hedge funds
ADAP

Simply Wall St.

7 months ago

Adaptimmune Therapeutics plc's (NASDAQ:ADAP) top owners are retail investors with 50% stake, while 25% is held by hedge funds

Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025
ADAP

Newsfile

8 months ago

Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025

Adaptimmune Therapeutics (NASDAQ:ADAP) investors are sitting on a loss of 86% if they invested five years ago
ADAP

Simply Wall St.

9 months ago

Adaptimmune Therapeutics (NASDAQ:ADAP) investors are sitting on a loss of 86% if they invested five years ago

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
ADAP

Newsfile

9 months ago

Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)

ADAP

MT Newswires

10 months ago

Adaptimmune Therapeutics Chief Financial Officer Gavin Wood to Resign in May 2025

Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK
ADAP

Newsfile

10 months ago

Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK

First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)
ADAP

Newsfile

10 months ago

First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)

ADAP

MT Newswires

a year ago

Mizuho Cuts Price Target on Adaptimmune Therapeutics to $1.50 From $3, Keeps Outperform Rating

Adaptimmune Therapeutics Third Quarter 2024 Earnings: Beats Expectations
ADAP

Simply Wall St.

a year ago

Adaptimmune Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Halozyme bids for Evotec; BeiGene gets a new name
ADAP

BioPharma Dive

a year ago

Halozyme bids for Evotec; BeiGene gets a new name

Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints
ADAP

Pharmaceutical Technology

a year ago

Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints

ADAP

Zacks Small Cap Research

a year ago

ADAP 3Q24 Earnings Review: Streamlining the Platform; Profitability Inflection Point in 2027

Adaptimmune Therapeutics PLC (ADAP) Q3 2024 Earnings Call Highlights: Strategic Restructuring ...
ADAP

GuruFocus.com

a year ago

Adaptimmune Therapeutics PLC (ADAP) Q3 2024 Earnings Call Highlights: Strategic Restructuring ...

Adaptimmune Reports Q3 2024 Financial and Business Updates
ADAP

Newsfile

a year ago

Adaptimmune Reports Q3 2024 Financial and Business Updates

Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial
ADAP

Newsfile

a year ago

Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial

Adaptimmune to Participate in Scientific and Medical Conferences this November and December
ADAP

Newsfile

a year ago

Adaptimmune to Participate in Scientific and Medical Conferences this November and December

Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024
ADAP

Newsfile

a year ago

Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024

ADAP

Zacks Small Cap Research

a year ago

OTC Markets Hosts Virtual Investor Presentation with Adrian Rawcliffe, CEO of Adaptimmune Therapeutics, and Michael Kim, Senior Analyst at Zacks SCR

Adaptimmune Therapeutics plc's (NASDAQ:ADAP) top owners are individual investors with 39% stake, while 28% is held by institutions
ADAP

Simply Wall St.

a year ago

Adaptimmune Therapeutics plc's (NASDAQ:ADAP) top owners are individual investors with 39% stake, while 28% is held by institutions

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
ADAP

GlobeNewswire

a year ago

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

Life Sciences Virtual Investor Forum Agenda Announced for September 19th
ADAP

GlobeNewswire

a year ago

Life Sciences Virtual Investor Forum Agenda Announced for September 19th

Adaptimmune to Participate in Two Bank Conferences this September
ADAP

Newsfile

a year ago

Adaptimmune to Participate in Two Bank Conferences this September

Adaptimmune Therapeutics (NASDAQ:ADAP) investors are sitting on a loss of 74% if they invested three years ago
ADAP

Simply Wall St.

a year ago

Adaptimmune Therapeutics (NASDAQ:ADAP) investors are sitting on a loss of 74% if they invested three years ago

ADAP

Zacks Small Cap Research

a year ago

ADAP: 2Q24 Earnings Review: Tecelra FDA Approval + Capital Reload

Adaptimmune Reports Q2 2024 Financial and Business Updates
ADAP

Newsfile

a year ago

Adaptimmune Reports Q2 2024 Financial and Business Updates

Adaptimmune leads in soft tissue sarcoma therapy with first TCR approval
ADAP

Pharmaceutical Technology

a year ago

Adaptimmune leads in soft tissue sarcoma therapy with first TCR approval

ADAP

Newsfile

a year ago

Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024

Adaptimmune’s Tecelra gains accelerated approval for synovial sarcoma
ADAP

Pharmaceutical Technology

a year ago

Adaptimmune’s Tecelra gains accelerated approval for synovial sarcoma

ADAP

MT Newswires

a year ago

Agilent Technologies' MAGE-A4 Test Approved by FDA for Use With T-Cell Receptor Therapy

ADAP

MT Newswires

a year ago

Sector Update: Health Care Stocks Decline Premarket Friday

FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade
ADAP

Benzinga

a year ago

FDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A Decade

First-of-its-kind cell therapy approved by FDA for rare soft tissue cancer
ADAP

BioPharma Dive

a year ago

First-of-its-kind cell therapy approved by FDA for rare soft tissue cancer

ADAP

MT Newswires

a year ago

Adaptimmune Therapeutics Gets Accelerated Approval of Tecelra From FDA

Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor
ADAP

Business Wire

a year ago

Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor

ADAP

MT Newswires

a year ago

HC Wainwright Starts Adaptimmune Therapeutics With Buy Rating, $4 Price Target

Why Are Hedge Funds Bullish on Adaptimmune Therapeutics plc (ADAP) Now?
ADAP

Insider Monkey

a year ago

Why Are Hedge Funds Bullish on Adaptimmune Therapeutics plc (ADAP) Now?

5 FDA decisions to watch in the third quarter
ADAP

BioPharma Dive

a year ago

5 FDA decisions to watch in the third quarter

ADAP

Zacks Small Cap Research

a year ago

Fireside Chat with Adrian Rawcliffe, Chief Executive Officer of Adaptimmune

ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company
ADAP

Zacks Small Cap Research

a year ago

ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company

FDA panel votes to recommend Eli Lilly's Alzheimer's drug
ADAP

Yahoo Finance Video

a year ago

FDA panel votes to recommend Eli Lilly's Alzheimer's drug

ADAP

GlobeNewswire

a year ago

Chu Vision Institute Unveils Comprehensive Guide to LASIK Recovery and Aftercare, Pioneering Patient Care in Minneapolis

California seeks company profits in Big Oil climate lawsuit
ADAP

Reuters

a year ago

California seeks company profits in Big Oil climate lawsuit

ADAP

USA TODAY

a year ago

S&P 500, Nasdaq post record closing highs; Fed meeting, CPI ahead

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock
ADAP

Business Wire

a year ago

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
ADAP

GlobeNewswire

a year ago

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research
ADAP

GlobeNewswire

a year ago

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas
ADAP

Business Wire

a year ago

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas

Lotto 6/49 - $64 million up for grabs in the next draw!
ADAP

CNW Group

a year ago

Lotto 6/49 - $64 million up for grabs in the next draw!

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture
ADAP

Simply Wall St.

a year ago

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Seoul says it will resume loudspeaker propaganda against North
ADAP

AFP

a year ago

Seoul says it will resume loudspeaker propaganda against North

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend
ADAP

Simply Wall St.

a year ago

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m
ADAP

Simply Wall St.

a year ago

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week
ADAP

Barrons.com

a year ago

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend
ADAP

Simply Wall St.

a year ago

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued
ADAP

Simply Wall St.

a year ago

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise
ADAP

Newsfile

a year ago

Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise

ADAP

MT Newswires

a year ago

Galapagos, Adaptimmune Therapeutics Team Up to Evaluate Head and Neck Cancer Drug

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
ADAP

Newsfile

a year ago

Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications

ADAP

MT Newswires

a year ago

Scotiabank Starts Adaptimmune Therapeutics With Sector Outperform Rating

ADAP

MT Newswires

a year ago

Mizuho Slashes Price Target on Adaptimmune Therapeutics to $3 From $9, Keeps Buy Rating

ADAP

MT Newswires

a year ago

Adaptimmune Therapeutics Enters Into $125 Million Term Loan Facility With Hercules Capital

Adaptimmune Reports Q1 2024 Financial and Business Updates
ADAP

Newsfile

a year ago

Adaptimmune Reports Q1 2024 Financial and Business Updates

Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital
ADAP

Newsfile

a year ago

Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital

Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024
ADAP

Newsfile

a year ago

Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024

Adaptimmune (ADAP) Down on End of Collaboration With Roche
ADAP

Zacks

a year ago

Adaptimmune (ADAP) Down on End of Collaboration With Roche

Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated
ADAP

Newsfile

2 years ago

Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated

Roche, Adaptimmune part ways on cell therapy research
ADAP

BioPharma Dive

2 years ago

Roche, Adaptimmune part ways on cell therapy research

Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet
ADAP

Newsfile

2 years ago

Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet

Adaptimmune Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
ADAP

Simply Wall St.

2 years ago

Adaptimmune Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Adaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results
ADAP

GuruFocus.com

2 years ago

Adaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript
ADAP

Insider Monkey

2 years ago

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript

Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates
ADAP

Newsfile

2 years ago

Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
ADAP

Newsfile

2 years ago

Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise

Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024
ADAP

Newsfile

2 years ago

Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024

15 Top Performing European Stocks So Far in 2024
ADAP

Insider Monkey

2 years ago

15 Top Performing European Stocks So Far in 2024

Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know
ADAP

Zacks

2 years ago

Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know

Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review
ADAP

Newsfile

2 years ago

Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review

Share on Social Networks: